GLUT-1 expression and response to chemoradiotherapy in rectal cancer.
Sheehan, Katherine M
McNamara, Deborah A
Bouchier-Hayes, David J
Kay, Elaine W
AffiliationDepartment of Surgery, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland. firstname.lastname@example.org
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Combined Modality Therapy
Glucose Transporter Type 1
Tumor Markers, Biological
Tumor Suppressor Protein p53
MetadataShow full item record
CitationGLUT-1 expression and response to chemoradiotherapy in rectal cancer. 2009, 125 (12):2778-82 Int. J. Cancer
JournalInternational journal of cancer. Journal international du cancer
AbstractPreoperative chemoradiotherapy is used in locally advanced rectal cancer to reduce local recurrence and improve operability, however a proportion of tumors do not undergo significant regression. Identification of predictive markers of response to chemoradiotherapy would improve patient selection and may allow response modification by targeting of specific pathways. The aim of this study was to determine whether expression of glucose transporter-1 (GLUT-1) and p53 in pretreatment rectal cancer biopsies was predictive of tumor response to chemoradiotherapy. Immunohistochemical staining for GLUT-1 and p53 was performed on 69 pretreatment biopsies and compared to tumor response in the resected specimen as determined by the tumor regression grade (TRG) scoring system. GLUT-1 expression was significantly associated with reduced response to chemoradiotherapy and increasing GLUT expression correlated with poorer response (p=0.02). GLUT-1 negative tumors had a 70% probability of good response (TRG3/4) compared to a 31% probability of good response in GLUT-1 positive tumors. GLUT-1 may be a useful predictive marker of response to chemoradiotherapy in rectal cancer.
- Pretreatment HIF-1α and GLUT-1 expressions do not correlate with outcome after preoperative chemoradiotherapy in rectal cancer.
- Authors: Havelund BM, Sørensen FB, Lindebjerg J, Spindler KL, Jakobsen A
- Issue date: 2011 May
- p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy.
- Authors: Saw RP, Morgan M, Koorey D, Painter D, Findlay M, Stevens G, Clarke S, Chapuis P, Solomon MJ
- Issue date: 2003 Feb
- Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis.
- Authors: Meng X, Wang R, Huang Z, Zhang J, Feng R, Xu X, Zhu K, Dou X, Chen D, Yu J
- Issue date: 2014 Jul
- A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
- Authors: Beddy D, Hyland JM, Winter DC, Lim C, White A, Moriarty M, Armstrong J, Fennelly D, Gibbons D, Sheahan K
- Issue date: 2008 Dec
- Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study.
- Authors: Hongo K, Kazama S, Tsuno NH, Ishihara S, Sunami E, Kitayama J, Watanabe T
- Issue date: 2015 Jan 27